University Prepares COVID-19 Vaccine Trial in South Africa
The South African Ox1Cov-19 Vaccine VIDA-trial developed by Wits University researchers is a first for Africa and one of 268 other candidate vaccines currently being researched and tested round the world. Shabir Madhi, Professor of Vaccinology at Wits University and Director of the South Africa Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, who leads the trial said: "This is a landmark moment for South Africa and Africa at this stage of the Covid-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by Covid-19."
As of March 1, confirmed cases of Covid-19 from 55 African countries reached 3,897,307. Reported deaths in Africa reached 103,706 and 3,469,842 people have ... Read more »
Hundreds of cases have been confirmed in Africa, while globally cases of the novel coronavirus have reached hundreds of thousands - here's how far we are in working towards rapid ... Read more »
Professor Shabir-Madhi explains the vaccine trial to a patient.